Steven M. Paul

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boston, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Troy Ignelzi, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Steven M. Paul

Form 4 holding Director

Karuna Therapeutics, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
18 Mar 2024
Price
$330.00
Ownership
Jann E. Paul GRAT III
Form 4 holding Director

Karuna Therapeutics, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
18 Mar 2024
Price
$330.00
Ownership
Jann E Paul Revocable Trust
Form 4 holding Director

Karuna Therapeutics, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
18 Mar 2024
Price
$330.00
Ownership
Steve M. Paul Family 2021 Delaware Trust
Form 4 holding Director

Karuna Therapeutics, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
18 Mar 2024
Price
$330.00
Ownership
Steven M. Paul Family 2024 Trust
Form 4 holding Director

Karuna Therapeutics, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
18 Mar 2024
Price
$330.00
Ownership
The Steven M Paul Revocable Trust
Form 4 holding Director

Karuna Therapeutics, Inc.

Security class
Option (right to buy)
Shares / value
0
Estimated value
$0
Report date
18 Mar 2024
Price
$142.74
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Seaport Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
991,192
Estimated value
Report date
30 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Voyager Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
15,000
Estimated value
Report date
03 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sage Therapeutics, Inc.

Security class
Stock Options (Right to buy)
Shares / value
3,971
Estimated value
Report date
03 Jan 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ALNYLAM PHARMACEUTICALS, INC.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
01 Apr 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Seaport Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
04 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Steven M. Paul

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .